We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2007 by Hormozgan University of Medical Sciences.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00432588
First Posted: February 8, 2007
Last Update Posted: June 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hormozgan University of Medical Sciences
  Purpose
Hypothesis (H0): Labor duration and obstetric complications are not significantly different in the three groups (misoprostol-dinoprostone-oxytocin).

Condition Intervention Phase
Preeclampsia Fetal Death Fetal Membranes, Premature Rupture Drug: misoprostol Drug: dinoprostone Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Hormozgan University of Medical Sciences:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Term pregnancy
  • Singleton
  • Vertex
  • Bishop score below 6

Exclusion Criteria:

  • History of drug reaction
  • Medical disease
  • IUGR
  • Oligohydramnios
  • Vaginal bleeding
  • Fetal anomaly
  • Uterine scar
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00432588


Locations
Iran, Islamic Republic of
Shariaty Maternity Hospital Not yet recruiting
Tehran, Iran, Islamic Republic of
Contact: Mitra Ahmad Soltani, MD    0098 021 22301004    m_a_sol@yahoo.com   
Sponsors and Collaborators
Hormozgan University of Medical Sciences
Investigators
Principal Investigator: Mitra Ahmad Soltani Hormozgan University of Medical Sciences
Study Chair: Minoo Rajaee Lari, Perinatologist - Obs and Gyn Department of Obs and Gyn - HUMS
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00432588     History of Changes
Other Study ID Numbers: Misoprostol vs Dinoprostone
First Submitted: February 6, 2007
First Posted: February 8, 2007
Last Update Posted: June 1, 2007
Last Verified: February 2007

Keywords provided by Hormozgan University of Medical Sciences:
IUFD
POSTTERM
ROM

Additional relevant MeSH terms:
Pre-Eclampsia
Rupture
Fetal Death
Fetal Membranes, Premature Rupture
Hypertension, Pregnancy-Induced
Pregnancy Complications
Wounds and Injuries
Death
Pathologic Processes
Obstetric Labor Complications
Misoprostol
Dinoprostone
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics